The purpose of this study is to look at the effects (good and bad) of the combination of docetaxel and carboplatin for patients who have progressive prostate cancer after chemotherapy with drugs such as docetaxel. We are also studying whether the measurement of two proteins in the blood may predict who will respond to the combination of docetaxel and carboplatin.

Condition	Intervention	Phase
Prostate Cancer Cancer of the Prostate Cancer of Prostate	Drug: Docetaxel  Drug: Carboplatin	Phase II

Further Study Details: 

Primary Outcomes: The primary objective is to determine the efficacy and safety of docetaxel plus carboplatin as salvage chemotherapy in patients with hormone refractory prostate cancer who have progressed on prior docetaxel-based chemotherapy.
Secondary Outcomes: The secondary objective is to correlate the clinical and PSA response with baseline serum chromogranin A (CGA) and neuron-specific enolase (NSE) levels.
Expected Total Enrollment:  30

• Patients will receive both carboplatin and docetaxel. This treatment is given in the outpatient department once every 3 weeks (called one cycle).
• One day prior to the day of chemotherapy, patients are given a steroid drug (dexamethasone) to be taken twice a day for 3 days. This helps to decrease the risk of an allergic reaction.
• On the day of chemotherapy, both docetaxel and carboplatin will be given through a vein over two to three hours. Docetaxel will be given before carboplatin. In addition, patients receive zofran, an anti-vomiting agent, to try to prevent nausea and vomiting. Study participants are also given a prescription for anti-nausea pills to take at home.
• After each cycle of treatment, patients are required to get their bloods checked (between days 8-12 of the cycle). This may be done at an outside laboratory closer to the patient''''s home.
• Treatment will be repeated every three weeks provided the blood tests and physical examination done prior to each treatment are acceptable. If a patient is not able to receive the next scheduled dose of chemotherapy, the doctor will delay the treatment for a week to a maximum of two weeks, beyond which, the patient will be taken off the trial. If there is a delay of more than one week or the study participant has significant side effects, their doctor will decrease the dose of the carboplatin and docetaxel. During the treatment period, doctors may also prescribe medications to treat low red blood cells or low white blood cells.
• Before each cycle (every 3 weeks), there will be routine blood tests drawn (about 3 teaspoons) to monitor bone marrow, liver, and kidney functions. These samples will look at two proteins in the blood and may help us predict who will respond to docetaxel and carboplatin. We will also obtain CT scans after every 3 cycles of treatment and at the end of the study. A bone scan will also be done after every 3 cycles if there was evidence of bone involvement on the first bone scan. A bone scan may also be ordered during the study in patients without prior evidence of bone involvement if the doctor suspects that the cancer has now spread to the bone.

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Male

Criteria

Inclusion Criteria:

• Histologically confirmed adenocarcinoma of the prostate
• Evidence of metastatic disease
• Disease progression following androgen deprivation therapy
• Disease progression despite docetaxel-based chemotherapy
• Serum testosterone levels less than 50ng/ml (unless surgically castrate). Patients must continue androgen deprivation with an LHRH analogue if they have not undergone orchiectomy.
• No use of antiandrogen for at least 4 weeks
• CALGB performance status less than or equal to 2
• Acceptable WBC, platelets, creatinine and AST counts

Exclusion Criteria:

• Significant peripheral neuropathy defined as grade 2 or higher
• Within 4 weeks since completing external beam radiotherapy or 8 weeks since completing radiopharmaceutical therapy (strontium, samarium)
• Prior platinum-based chemotherapy (cisplatin or carboplatin) for hormone- refractory prostate cancer
• Concomitant chemotherapy, investigational agents or systemic steroids

Massachusetts
      Dana-Farber Cancer Institute, Boston,  Massachusetts,  02115,  United States
      Massachusetts General Hospital, Boston,  Massachusetts,  02114,  United States
      Beth Israel Deaconess Medical Center, Boston,  Massachusetts,  02215,  United States
      Lowell General Hospital, Lowell,  Massachusetts,  01854,  United States
New Hampshire
      Wentworth Douglass Hospital, Dover,  New Hampshire,  03820,  United States
Oregon
      Oregon Health and Science University, Portland,  Oregon,  97239,  United States

Study chairs or principal investigators

William K Oh, MD,  Principal Investigator,  Dana-Farber Cancer Institute   

Study ID Numbers:  03-319
Last Updated:  August 24, 2005
Record first received:  August 24, 2005
ClinicalTrials.gov Identifier:  NCT00134706
Health Authority: United States: Institutional Review Board
ClinicalTrials.gov processed this record on 2005-08-30